The best biotech stocks right now are Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron (REGN), argenx (ARGX), Alnylam (ALNY), and Exelixis (EXEL).
Six of these seven companies now generate more than $1 billion in quarterly revenue. That scale separates this list from speculative biotech names that depend on one clinical trial or a single FDA ruling.
This guide favors drugmakers with approved medicines, proven demand, cash to fund research, and pipelines that can add new growth. The tradeoff is that even strong biotech companies face patent losses, pricing pressure, competition, and clinical setbacks.
How We Picked These Stocks
This screen starts with the existing seven picks and keeps them because each remains a U.S.-listed, commercial-stage biotech company with an established drug franchise and meaningful development pipeline. Companies were ranked by market capitalization. We looked for recent revenue growth, product concentration, profitability or a clear route to it, financial flexibility, and identifiable catalysts. We excluded pre-revenue developers, micro-cap trial bets, companies reliant on a single unproven asset, and large pharmaceutical companies whose biotech exposure is only one part of a broader business.
The Best Biotech Stocks
Amgen (NASDAQ: AMGN)
Why it made the list: Amgen is the largest and most diversified company on this list. First-quarter revenue rose 6% to $8.6 billion, while 16 brands delivered double-digit sales growth. That broad base gives Amgen room to absorb pressure from older medicines while funding its late-stage pipeline and dividend.
The bull case: Growth from newer products can offset losses from aging franchises and support steady cash generation.
The risk: Amgen carries a large debt load from past acquisitions. Faster-than-expected price pressure or weaker launches would make that balance sheet more important.
Key number: 16 brands posted double-digit sales growth.
Gilead Sciences (NASDAQ: GILD)
Why it made the list: Gilead combines a large HIV franchise with growing oncology and liver-disease businesses. First-quarter product sales excluding Veklury rose 8% to $6.8 billion, and management raised its full-year product sales outlook to $30.0 billion to $30.4 billion. Its dividend also gives the stock a different return profile from most biotech peers.
The bull case: HIV remains a durable cash engine, while oncology investments could create a second major growth leg.
The risk: The company is spending heavily on acquisitions, including Arcellx. The financial return depends on whether those assets become meaningful commercial products.
Key number: 2026 product sales outlook: $30.0 billion to $30.4 billion.
Vertex Pharmaceuticals (NASDAQ: VRTX)
Why it made the list: Vertex still leads cystic fibrosis treatment, but its growth case is becoming broader. First-quarter revenue rose 8% to $2.99 billion, and newer products CASGEVY and JOURNAVX supplied more than one-quarter of the company's growth. The company is also building a kidney-disease franchise around povetacicept.
The bull case: Commercial progress outside cystic fibrosis would reduce dependence on one franchise and expand Vertex's addressable market.
The risk: Cystic fibrosis remains the financial core. Newer medicines must scale fast enough to justify rising research, launch, and acquisition spending.
Key number: First-quarter revenue growth: 8%.
Regeneron Pharmaceuticals (NASDAQ: REGN)
Why it made the list: Regeneron has one of biotech's strongest combinations of profitable products and internal research. First-quarter revenue grew 19% to $3.6 billion, helped by Dupixent and EYLEA HD. The company also authorized a new $3.0 billion share repurchase program.
The bull case: Dupixent's expanding use across inflammatory diseases can keep supporting earnings while Regeneron develops new eye, cancer, and rare-disease medicines.
The risk: The older EYLEA franchise is under pressure. Combined U.S. sales of EYLEA and EYLEA HD fell 10% in the first quarter despite strong EYLEA HD growth.
Key number: First-quarter revenue growth: 19%.
argenx (NASDAQ: ARGX)
Why it made the list: argenx has turned VYVGART into a rapidly growing immunology franchise. Second-quarter VYVGART product sales reached $1.5 billion, up 60% from a year earlier, after the drug's U.S. label expanded to include all adult patients with generalized myasthenia gravis. The company is now using that commercial base to pursue more autoimmune diseases.
The bull case: More VYVGART indications could increase patient access, while empasiprubart gives argenx a potential second product platform.
The risk: VYVGART supplies nearly all current product revenue. A slower launch in new indications or stronger competition in autoimmune disease would have an outsized effect.
Key number: Second-quarter VYVGART sales: $1.5 billion.
Alnylam Pharmaceuticals (NASDAQ: ALNY)
Why it made the list: Alnylam is proving that RNA interference drugs can become large commercial franchises. First-quarter product revenue reached $1.036 billion, up 121%, led by $910 million in transthyretin amyloidosis sales. Management expects combined 2026 product revenue of $4.9 billion to $5.3 billion.
The bull case: AMVUTTRA's expansion in heart disease could make Alnylam a much larger cardiovascular company, not just a rare-disease specialist.
The risk: The valuation depends on sustained uptake in a newer and larger patient population. Reimbursement delays or slower physician adoption would weaken the growth case.
Key number: First-quarter product revenue growth: 121%.
Exelixis (NASDAQ: EXEL)
Why it made the list: Exelixis offers a profitable oncology business with more financial discipline than many smaller biotech firms. First-quarter revenue reached $610.8 million, including $555.0 million of U.S. net product revenue from its cabozantinib franchise. The company also authorized up to $750 million in additional share repurchases through 2027.
The bull case: New uses for cabozantinib and progress with zanzalintinib could extend Exelixis beyond its current kidney-cancer base.
The risk: Cabozantinib remains the central earnings driver. A clinical setback or a sharper competitive threat would expose the company's product concentration.
Key number: U.S. cabozantinib revenue: $555.0 million in the latest quarter.
Biotech Sector Overview
Biotech is becoming more selective. The best returns are increasingly going to companies that can turn scientific advances into recurring drug sales, rather than simply announce early trial data. Immunology is a major growth area for argenx and Regeneron. RNA-based medicine is moving into broader heart-disease markets through Alnylam. Vertex is working to turn cystic fibrosis cash flow into new franchises in pain, kidney disease, and genetic medicine.
The sector still carries more event risk than most industries. A late-stage trial can fail, an FDA decision can delay a launch, and insurers can limit patient access to expensive medicines. That is why revenue quality matters. The stronger companies have approved products paying for research, while their pipelines provide the next source of growth. This list balances mature cash generators with faster-growing franchises that have already cleared the hardest commercial hurdle: finding real demand.
What to Watch
- Regeneron's second-quarter earnings call on July 30 at 8:30 AM ET. Watch EYLEA trends, Dupixent growth, and updates on its eye and immunology pipeline.
- Second-quarter results from Vertex on August 3, Gilead on August 4, and Exelixis on August 5. Revenue guidance and launch progress will matter more than headline earnings.
- Vertex's FDA decision on povetacicept for IgA nephropathy is due by November 30. argenx also expects a registrational myositis study readout in the third quarter.
The Bottom Line
This list is for investors who want biotech exposure without relying on pre-revenue trial bets. Amgen and Gilead bring scale and cash flow. Vertex, Regeneron, argenx, Alnylam, and Exelixis offer more growth tied to expanding drug franchises. Compare each company's product concentration, pipeline timing, and role in a broader portfolio before choosing among them.
Frequently Asked Questions
What makes a biotech stock different from a pharmaceutical stock?
Biotech companies often focus on medicines made through advanced biology, such as antibodies, gene therapies, or RNA-based drugs. Pharmaceutical companies are usually more diversified and may have larger portfolios of traditional medicines. The line can blur as successful biotech companies grow.
Which biotech stocks on this list pay dividends?
Amgen and Gilead pay regular dividends. Most growth-focused biotech companies, including Vertex, Regeneron, argenx, Alnylam, and Exelixis, reinvest more of their cash into research, acquisitions, and launches.
Why is Vertex Pharmaceuticals one of the top biotech stocks?
Vertex has a dominant cystic fibrosis franchise that produces substantial cash flow, plus newer products in acute pain and genetic disease. Its next major test is whether kidney-disease medicine povetacicept can become another large franchise.
Are biotech stocks riskier than most large-cap stocks?
Often, yes. Drug trials, FDA reviews, patent expirations, competition, and insurance coverage can change a company's outlook quickly. Companies with several approved drugs and recurring revenue are generally less exposed than one-drug or pre-revenue biotech firms.
What should investors check before buying a biotech stock?
Start with the company's main drug, how fast its sales are growing, and how much of total revenue comes from that product. Then check the next major trial result, FDA decision, patent risk, debt, cash balance, and whether the pipeline can replace older medicines.
